Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bendamustine + lenalidomide + rituximab
- Development stage
- Unknown
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination regimen consisting of three drugs—bendamustine (an alkylating agent), lenalidomide (an immunomodulatory drug), and rituximab (a monoclonal antibody targeting CD20). The combination has been studied in various B-cell malignancies including non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL). Bendamustine induces DNA crosslinking leading to apoptosis; lenalidomide modulates the immune system and inhibits angiogenesis; rituximab binds to CD20 on B cells, mediating cell lysis via immune mechanisms. This regimen is typically used in relapsed/refractory or previously untreated patients who have failed standard therapies. Clinical trials have shown varying efficacy and toxicity profiles depending on disease context[1][2][3][6][8][10].
- Brand names
- TreandaRituxanRevlimid
- Other names
- bendamustine lenalidomide rituximabBLRBRLR2BR-2BR 2B
02
Targets
Beyond the preview
Go deeper on bendamustine + lenalidomide + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bendamustine + lenalidomide + rituximab.